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Effects of rhGH and rhIGF-1 on renal growth and morphology It is
known that in rodents recombinant human growth hormone (rhGH) and
recombinant human insulin-like growth factor (rhIGF-l) increase renal
mass. It is uncertain, however, whether renal mass increases in
proportion to body growth, or whether renal growth is stimulated
selectively. In 120 to 150 g female Sprague-Dawley rats, we measured
the effects of rhGH and rhIGF-l and their combination by the following
parameters: kidney weight/body weight ratio, DNA/protein ratio,
mRNA of GH receptor and of IGF-l, mitosis index and PCNA (by
immunohistology), zonal architecture and glomerular diameter by mi-
cromorphometry. Both rhGH and rhIGF-l dose-dependently increased
renal weight and body weight over vehicle treated controls. With rhGH,
liver dry weight/body weight ratio increased, but kidney dry weight!
body weight ratio remained unchanged (0.99 0.06 x i0 vs. 1.02
0.07 in vehicle controls). In contrast, a significant increase of kidney dry
weight/body weight ratio was seen in rats treated with rhIGF- 1 (1.3
0.21 x l0). Addition of high doses of rhGH to high doses of rhIGF-1
caused no further increase of the ratio despite a significant further
increase of body weight. rhGH increased the abundance of renal GH
receptor mRNA (0.46 0.32amolljsg DNA vs. 0.08 0.07 in controls)
and of IGF-1 mRNA (1.35 0.5 pg/tg DNA vs. 0.35 0.17), whereas
no change was seen with IGF-l treatment. rhGH and rhIGF-1 increased
kidney DNA/protein ratio, mitoses and PCNA expression in various
renal structures. Further stimulation of mitoses by rhGH was seen even
after subtotal nephrectomy, which was associated with markedly stim-
ulated baseline proliferation of renal cells. The results document that
rhGH increases renal weight in proportion to body weight while
rhIGF-l increases it out of proportion to body weight. Both peptides
increase renal glomerular and tubular cell proliferation and renal
DNA/protein ratio. This observation points to a major role of hyper-
plasia in renal weight gain of young female animals treated with the
peptides. The size of glomeruli increased, but the increment was in
proportion to body weight. Glomeruloscierosis was not detected even
after 60 days of treatment with rhGH or with rhIGF-1.
Acromegaly is associated with reversible nephromegaly and
increased glomerular filtration rate (GFR) [1—3]. Furthermore, it
is known that extractive growth hormone (GH) [4] or recombi-
nant OH [5] and insulin-like growth factor (IGF)-1 [6] raise GFR.
Recombinant human (rh) GH promotes growth in uremic
animals [7—9] and uremic children [10], and is therefore widely
used for the treatment of growth retardation in children with
renal failure. Concern has been raised that stimulation of GFR
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and renal growth might accelerate progression of renal failure,
since both hyperfiltration [11] and glomerular enlargement [12]
are important determinants of progression of renal failure.
Although renal failure is not a known consequence of acromeg-
aly [13], this concern is well founded since glomeruloscierosis
occurs in transgenic mice expressing the OH gene [14, 15].
It has been shown that renal weight is increased in transgenic
mice expressing OH [14, 16], in acromegalic rats bearing GH
producing hypophyseal tumors [17], and rats treated with rhGH
[18—20]. It is currently unknown, however, whether rhGH and
rhIGF-l have specific renotropic effects, that is, whether renal
growth outstrips body growth, or whether they stimulate renal
growth in proportion to body growth. The present study was
carried out to address this issue.
Methods
Animals
Female Sprague-Dawley (SD) rats (Ivanovas Co., Kisslegg/
Allgau, Germany), weighing 120 to 150 g, were used for the
experiments I to 8. Female rats were chosen because a better
response to growth hormone in female rats had previously been
documented by others [8]. One week prior to the study, the
animals were transferred to single cages at constant room
temperature (24°C) and humidity (70%) on a 12 hour on/12 hour
off light cycle. The diet contained 13800 kJ/kg, 0.95% calcium,
0.8% phosphorus, 500 lU/kg vitamin D3, and 18% protein
(wt/wt). Experimental animals and controls had free access to
food (Altromin C 1000 diet, Altromin Co., Lage/Lippe, Ger-
many) and deionized water.
The experiments I to 8 were not contemporaneous. In each
experiment, animals were assigned to the experimental or
control groups using random numbers.
In experiment 8, the animals were subjected to two-stage
subtotal nephrectomy (NX) or sham operation as described
previously [7, 21]. Subtotal nephrectomy of the left kidney was
performed one week prior to surgical removal of the right
kidney. At this moment, the animals had a mean body weight of
136 g. Control animals (Co) were sham-operated (renal decap-
sulation). The control group was pair fed as previously de-
scribed [7].
Recombinant peptides
rhGH and rhIGF- I were administered subcutaneously twice
daily in doses indicated under Protocols. rhGH (Genotropin)
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Table 1. Dose dependent effect of rhGH for seven days on growth in SD rats
rhGH
lU/kg/day
Weight gain
g
Length gain
cm
Cumulative food
intake g/7 days
Weight gain g
food intake g
Kidney dry
weight mg
Kidney dry weight g
body weight g
Vehicle 16.4 7.1 1.93 0.29 91 10 0.17 0.07 168 16 1.0 0.06
2.5 32.1 4.9" 2.30 0.29a 97 13 0.33 0.03" 179 14 0.97 0.07
5.0 36.0 61b 2.54 010b 98 8 0.36 0.04" 179 3 0.96 0.03
10.0 35.4 6.1" 2.62 0.39" 96 11 0.36 186 10 1.0 0.04
20.0 41.0 6.1" 2.61 0.29" 106 9 0.39 0.05" 188 7 0.97 0.03
N = 6 animals per group.
Significant difference between vehicle group and experimental group ( P < 0.05, b p < 0.01)
Table 2. Organ weight/body weight ratio under rhGH treatment with
increasing duration of treatment
Treatment
duration
Kidney dry weight g
body weight g x 10
Heart dry weight g
body weight g X 10
10 IU 10 IU
days rhGH/kg/day Vehicle rhGH/kg/day Vehicle
0 1.19 0.05 0.98 0.04
4 1.11 0.04 1.14 0.05 0.98 0.05 0.95 0.08
8 1.03 0.05 1.11 0.04 0.90 0.05 1.02 0.13
11 1.10 0.20 1.10 0.08 0.94 0.03 0.94 0.04
21 1.25 0.12 1.24 0.06 0.95 0.06 0.95 0.05
60 0.88 0.06 0.88 0.06 0.70 0.04 0.77 0.07
N = 7 animals per group.
was provided by Kabi Pharmacia Peptide Hormones (Stock-
holm, Sweden), rhIGF-l by Ciba-Geigy Co. (Basel, Switzer-
land; CGP 35' 126), and by Kabi Pharmacia Peptide Hormones
(Stockholm, Sweden; CH/B/60229—51).
Protocols
Experiment 1: Dose dependent effects of rhGH for seven days
on growth in SD rats (Table 1). Five groups of healthy animals
(N = 6animals per group) were treated with increasing doses of
rhGH ranging from 0 to 20 lU/kg/day given in two divided doses
s.c. for a period of seven days.
Experiment2: Time course of the effect oflOIUrhGH/kg/day
on growth in SD rats (Table 2). Five groups of healthy animals
(N = 7 animals per group) were treated with 10 IU rhGH/kg day
s.c. in two divided doses for various time intervals ranging from
four to 60 days.
Experiment 3: Dose- and time-dependent effects of rhIGF-1
on growth in SD rats (Table 3). Six groups of healthy animals (N
= 7 animals per group) were treated with increasing doses
rhIGF-l ranging from 0 to 16 mg/kg/day in two divided doses
s.c. for a period of seven days. Five animals were treated with
3 mg rhIGF-1/kg/day for 60 days.
Experiment 4: Effects of concomitant treatment with rhGH
(20 lU/kg/day) and rhIGF-1 (8 mg/kg/day) for 14 days on growth
in SD rats (Table 4). The number of animals was 10 for the three
treatment groups (20 IU rhGH/kg/day; 8 mg rhIGF-l/kg/day; 20
IU rhGH + 8 mg rhIGF-l/kg/day) and for the control (vehicle)
group. Peptides and vehicle were injected in two divided doses
twice daily s.c.
Experiment 5: Effect of rhGH (JO lU/kg/day) and of rhIGF-1
(3 mg/kg/day) forfive days on GHR mRNA and IGF-1 mRNA in
kidney and liver tissue (Table 5). The number of animals was
seven for the vehicle and treatment groups. Peptides and
vehicle were injected in two divided doses twice daily s.c.
Experiment 6: Effects of 10 IU rhGH/kg/day for 14 days on
renal morphology in SD rats (Table 6). Nine animals were
studied in the treatment and control (vehicle) groups, respec-
tively. The animals were injected with 10 IU rhGH/kg/day s.c.
in two divided doses twice daily. At the end of the experiment,
the kidneys were fixed by perfusion technique for analysis of
renal architecture and glomerular stereology.
Experiment 7: Effect of treatment with rhGH (10 lU/kg/day)
or rhIGF-J (4 mg/kg/day) for five days on renal DNA/protein
ratio in SD rats (Table 7). The number of animals was seven for
the treatment and for the control (vehicle) groups. The animals
were injected with 10 IU rhGH/kg/day or 4 mg rhIGF-1/kg/day,
respectively. The peptides were administered s.c. in two di-
vided doses twice daily.
Experiment 8: Effect of treatment with rhGH (10 lU/kg/day) or
rhIGF-1 (4 mg/kg/day) for 4 days on mitoses and PCNA expres-
sion of tubular and glomerular cells (Table 8). The number of
animals was seven for the treatment groups [renal intact animals
and subtotally nephrectomize (NX) animals treated with rhGH or
with rhIGF-1] and the control groups (renal intact animals and
subtotally NX animals treated with vehicle). All groups had free
access to food. The renal intact animals were pair fed to subtotally
NX animals. The animals received 5 i.p. injections of colchicme
(Demecolcin, Serva Co., Heidelberg, Germany) or vehicle at 30
minute intervals prior to the end of the experiment in the morning
hours (yielding a total colchicine dose of 800 .ig). Kidneys were
excised under anesthesia and fixed in 5% buffered formalin. A
second set of animals was not pretreated with coichicine prior to
death. Renal tissue was fixed in methyl Camoy's solution and
processed for detection of PCNA.
Analytical techniques
In vivo measurements. Body weight was measured during the
afternoon in non-fasting animals. Food intake was measured
daily and food conversion ratio (weight gain per food intake)
was calculated [8]. Nose to tail tip distances were measured in
anaesthesized animals under complete muscle relaxation as
described previously [21]. Blood pressure was measured by tail
plethysmography as described previously [21].
Organ weight. The animals were sacrificed by aortic puncture
under intramuscular anesthesia (30 mg/kg Ketanest, Park Davis
Co., Berlin, Germany and 0.3 mg/kg Valium, Hoffmann La
Roche, Grenzach-Wyhlen, Germany). Organs were weighed
before and after desiccation (24 hr; 80°C in the presence of
desiccant). Kidney volume was quantitated by measuring the
volume of water displaced after submersion.
Biochemistry and hormonal measurements. Serum biochem-
istry was analyzed using a multichannel Technicon Autoana-
lyzer (Technicon Instruments, Tarrytown, New York, USA).
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Table 3. Dose dependent effect of rhIGF- 1 for seven days on growth in SD rats
rhIGF-1 Weight gain Length gain Cumulative Weight gain g dney Kidney dry weight g > lo-
mg/kg/day g cm food intake g food intake g dry weight mg body weight g
Vehicle 25.6 3.0 2.81 0.30 117 9 0.21 0.03 158 6 1.06 0.06
1 33.0 4.1" 3.33 0.28a 109 9 0.25 O.O4 170 8 1.09 0.04
2 34.3 50b 3.80 0.70" 132 13 0.26 0.04a 175 12 1.10 0.04
4 35.4 5.3" 3.84 040b 104 10 0.34 005b 180 6 1.13 0.03k
8 39.6 6.9k' 4.04 0.16" 113 12 0.35 0.05" 189 14 1.15 0.08''
16 40.2 33b 4.20 02b 112 9 0.36 0.03" 193 16 1.18 0.08"
N = 7 animals per group
Significant difference between vehicle group and experimental group ( P < 0.05; b P < 0.01)
Table 4. Effect of concomitant treatment with rhGH (20 lU/kg/day) and rhIGF-l (8 mg/kg/day) for 14 days on growth in SD rats
Vehicle rhGH rhIGF-l rhGH + rhIGF-1(N = 10) (N = 10) (N = 10) (N = 10)
Initial weight g 135.9 5.6 136.0 5.6 135.3 6.0 135.8 5.9
Final weight g 178.9 9.9 219.3 8.2" 202.1 l0.3c 236.6 7.4°
A Weight g 43.0 5.6 83.3 7.6" 66.8 7.2c 100.8 6.5°
Initial length cm 33.1 0.9 33.1 0.8 33.2 0.9 33.2 0.6
Final length cm 36.8 0.7 39.1 0.7" 39.3 0.8 39.9 0.5
A Length cm 3.7 0.7 6.0 09' 6.1 0.7c 6.7 0.7
Kidney dry weight mg 182 15 216 18" 269 42C 266 34°
Liver dry weight mg 2,121 160 3,195 210" 2,955 172C 3,695 320°
Spleen dry weight mg 109 16 141 15'' 153 19C 164 18
Heart dry weight mg 160 8 195 13b 185 17C 212 19
Muscle dry weight mg 342 40 392 44° 367 37 399 22
Kidney dry weight 1.02 0.07 0.99 0.06 1.30 0.21c 1.12 0.13"
body weight X 10
a p < 0.05, b P < 0.01, rhGH vs. vehicle
P < 0.01, rhIGF-1 vs. vehicled P < 0.05; e p < 0.01, rhGH + rhIGF-1 vs. rhGH
Table 5. Effect of 3 mg rhIGF-1/kg/day or 10 IU rhGH/kg/day for
five days on growth hormone receptor (GHR) mRNA and IGF-l
mRNA in kidney and liver
Vehicle rhGH rhIGF-l
Kidney
IGF-1 mRNA 0.35 0.17 1.35 0.5° 0.6 0.33
pg//2g DNA
GHR mRNA 0.08 0.07 0.46 0.32° 0.16 0.14
amol/sg DNA
Liver
IGF-l mRNA 30.7 12.5 43.0 11.05 30.9 4.94
pg/pg DNA
GHR mRNA 3.28 0.55 2.69 0.43 3.3 0.43
amol/pg DNA
N = 7 animals per group.
P < 0.001, rhGH vs. vehicle and rhIGF-1 (ANOVA)
Creatinine was determined by a kinetic method according to Jaffé
without deproteinization; the within assay coefficient of variation
was <3%. Measurements of rhGH, rhIGHF-1 and of rat GH were
done by RIA techniques as described earlier [10, 18].
Chemical analysis of renal tissue. Renal tissue was frozen in
liquid nitrogen and powdered. Total protein was measured
according to Lowry. DNA was measured using a modified
method according to Blin and Stafford [22]. In brief, tissue
frozen in liquid nitrogen was powdered, 100 mg were mixed
with the lysis buffer (0.075 M NaCI, 0.024 M ETDA, 0.02 M
SDS, 1 M NaHPO4) and extracted with 1:1 phenol-chloroform
Table 6. Effect of 10 IU rhGH/kg/day for 14 days on renal
morphology in SD rats
Vehicle
(N=18)
rhGH
(N=18)
Body weight g 176 8.2 199 7.9
Kidney volume° cm3 1.04 0.06 1.18 0.08"
Cortex volume % of total kidney 78.4 2.6 78.4 2.4
volume
Width of cortex ÷ medulla mm 8.60 0.75 8.80 0.54
Width of outer + inner medulla mm 6.10 0.71 6.30 0.56
Width of inner medulla mm 4.20 0.50 4.40 0.47
Glomerular area pin2
Glomerular (3D) diameter pin
84S1 430
137.2 3.5
8951 321"
140.5 2.8"
a After perfusion fixationb p < 0.05 vehicle vs. rhGH
and 24:1 chloroform-isoamylalcohol (vol/vol). After precipita-
tion with isopropanolol, DNA was quantitated photometrically.
Solution hybridization for GH receptor mRNA and IGF-1
mRNA in renal and liver tissue. (a) GH-receptor mRNA probe.
A pT7T3 18 U vector carrying a 560 base pair BamHI fragment
[23] was linearized with EcoRI cleaving in the cloning box of
the vector, and labeled ([32P]UTP or [35S]UTP) cRNA was
generated with T3 polymerase (Promega, Madison, Wisconsin,
USA) under the conditions indicated by the manufacturer.
(b) IGF-1 mRNA probe. The radioactive probe was prepared as
described by Melton et a! [24]. In brief, the DNA clone used was
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Table 7. DNA/protein ratio of kidney in rhGH and IGF-l treated
SD rats
Vehicle
rhGH
10 lU/kg/day
rhIGF-l
4 mg/kg/day
Bodyweightg 141±6 159±6 143±4
Weightf5 days g 22.9 2.6 40.4 5.9 25.6 2.5
Kidney dry weight mg 136 8 143 8 144 15
left kidney
Protein content mg 47.2 4.6 53.9 8.0 58.5 49a
right kidney
DNA content pg 1344 395 3031 923° 3432 692k
DNA/protein 30.1 10.6 58.8 23.4° 59.0 l2.6a
ratio pg/mg
N = 7 animals per group; duration of treatment 5 days.
a P < 0.05 difference treatment group vs. vehicle
a 153 bp genomic subclone of pSP64 in both orientations of mouse
IGF-l corresponding to exon 3 (by analogy with human IGF-l).
Analyses of cDNA clones for IGF-1 indicate that two forms of
IGF- 1 mRNA could exist [25]. The structure of the probe used in
this study would allow detection of both forms of IGF-l mRNA.
GH receptor (GHR) mRNA was quantified by solution hybrid-
ization as previously described [26]. In brief, the tissue was
homogenized in a buffer containing 1% NaDodSO4, 20 mM Tris-
HCI (pH 7.5), and 4 mrvi EDTA and digested with protemase-K
(200 zg/ml) at 35°C for 35 minutes. Total nucleic acids (TNA) were
then extracted with phenol-chloroform. The TNA samples were
prepared from liver and kidney tissue from individual rats.
TNA samples were hybridized at 70°C for 24 hours in 0.06
mM NaCI, 20 mM Tns-HC1 (pH 7.5), 4 mM EDTA, 0.1%
NaDodSO4, 10 mrs dithiothrol, and 25% formamide (vol/vol)
with a "S-labeled GH-receptor cRNA probe in a volume of 40
td. The samples were then treated with 40 pg RNase A and 2 pg
RNase T1 in the presence of 100 jg herring sperm DNA for 45
minutes at 37°C in a volume of I ml. Protected probe was
precipitated with 100 .d trichioracetic acid (6 mol/liter), col-
lected on glass-fiber filters (GF/C, Whatman International Ltd.,
Maidstone, UK) and counted in a scitillation counter. A tissue
TNA preparation, originally compared with an in vitro tran-
scribed OH-receptor mRNA, was used to generate a standard
curve. The standard curve was linear between 0.1 and 16 amol.
The DNA content of the samples was analyzed [27], and 10 to
45 pg DNA in samples were assayed. Within this range, the
hybridization signal paralleled the standard curve. In all assays,
the lowest concentration of GH receptor mRNA measured was
well above the lowest point of the standard curve. Each TNA
sample was analyzed in duplicate. The results are expressed as
the amount of GHR mRNA per DNA (amolIpg). The coefficient
of variation was 6% within and between experiments.
The solution hybridization assay for quantification of IGF- 1
mRNA was described earlier [28]. It contained principally the
same steps as the assay for quantification of GHR mRNA. The
hybridization signal was compared with that of a tissue standard
curve originally compared with known amounts of the synthetic
153 nucleotide mRNA strand, as described previously [29].
Results are expressed as the amount of IGF- 1 mRNAIDNA
(pg/sg). Each sample was analyzed in duplicate. The within-
assay coefficient of variation (C.V.) was less than 20% in the
range of 40 to 400 amol of the RNA standard. The between-
assay C.V. was estimated by repeated analysis of the same
TNA preparation and was 23%.
Mitosis counts in renal tissue and immunoperoxidase stain-
ing. (a) Counting of tubular cell mitoses in renal tissue. HE
stained 8 js sections of paraffin embedded tissue were used as
described before [30]. Mitoses were counted at 400 x magnifi-
cation using a Zeiss Co. Integrationsplatte 11100/25. Mitoses
were counted in 50 fields each in the cortex, outer stripe, inner
stripe and inner medulla using a systematic random sampling
technique.
(b) Immunoperoxidase staining for counting glomerular cell
prolferation. Four micrometer sections of methyl Carnoy's
fixed renal tissue were processed by an indirect immunoperox-
idase technique as previously described [31]. The proliferating
nuclear antigen (PCNA), which is expressed by actively prolif-
erating cells [32], was detected using l9A2 (Coulter Electronics,
Hialeah, Florida, USA), a murine 1gM monoclonal antibody
against human PCNA. For all tissues, negative controls con-
sisted of substitution of the primary antibody with equivalent
concentrations of an irrelevant munne monoclonal antibody. In
each kidney, over 40 cross sections (range 40 to 80) of consec-
utive cortical glomeruli containing more than 20 discrete capil-
lary segments each were evaluated by a person who was
unaware of the origin of the slides. Mean values per kidney
were then calculated for the number of proliferating (PCNA+)
cells per glomerular cross section.
Renal histology and renal morphometry. For histological
evaluation of glomerulosclerosis and tubulointerstitial lesions in
experiment 2 and experiment 3, the kidneys were fixed in
formalin stained with hematoxylin/eosin and analyzed by light
microscopy.
For morphometric studies, the viscera were fixed by retro-
grade vascular perfusion at a pressure of 110 mm Hg after
catheterization of the distal abdominal aorta. Before fixation,
the vascular system was flushed, with a dextran solution
(Rheomacrodex'; Schiwa Co., Glandorf, Germany) containing
0.5 g/liter procaine HC1. The vena cava inferior was incised to
drain the blood.
The kidney was dissected into 1 mm thick slices cut perpen-
dicularly to the interpolar axis. The specimen was embedded in
paraffin and cut into 4 sm thick slices and then stained with
hematoxylin/eosin. For area measurements, a semiautomatic
image analyzing system (Videoplan, Kontron Co., Eching,
Germany) was used. At a magnification of x 10, the area
fraction of the cortex and medulla was determined and volume
density and total volume were calculated as described [33]. At
a magnification of x 400, the mean area of glomerular profiles
was measured. Data are given as mean cross sectional area of
glomeruli. The diameters were determined by identifying the
inner edges of the thin parietal layer of cells forming Bowman
capsule in every sixth consecutive glomerular section. Assum-
ing a spherical size of glomeruli, the true three-dimensional
diameter (stereological diameter) was obtained from the size
distribution of diameters according to Weibel [33].
Statistics
Data are given as X SD or as mean (range). Results were
evaluated using Wilcoxon's test for random samples or paired
differences and by ANOVA.
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Table 8. Effect of rhGH and of rhIGF-I on mitoses in tubular cells of SD rats
Treatment Renal status
Number of mitoses/mm2
Distal tubule Proximal tubule Total tubules
Vehicle intact 8.3 3.9 10.0 5.4 18.3 8.0
IOIUrhGH/kg/day intact 12,2 5,Ø 17.7 6.9t 29.9
Vehicle subtotal NX 140.9 29.7 209.8 45.6 350.7 67.8
10 IU rhGH/kg/day subtotal NX 168.0 22.2a 325.6 30.3'' 493.6 38.6a
Vehicle intact 8.3 1.9 12.8 2.5 21.1 4.2
4 mg rhIGF-1/kg/day intact 13.0 2.2k' 20.3 44a 55b
Vehicle subtotal NX 130.3 13.7 267.3 14.8 397.6 25.8
4 mg rhIGF-lIkg/day subtotal NX 163.3 153b 349.8 338b 513.4 437b
Duration of treatment was 4 days.
N = 7 animals per group.
a P < 0.05 and b P < 0.01 rhGH vs. vehicle or rhIGF-l vs. vehicle
Results
Dose-dependent effects of rhGH for seven days on growth in
SD rats
Short term s.c. administration of 2.5 to 20.0 IU of rhGH/kg/day
in two divided doses caused significant increments in weight and
length with inconsistent effects on cumulative food intake, but
caused a signfficant increase of the food conversion ratio, that is,
weight gain per food intake (Table 1). There were no significant
effects on systolic blood pressure (vehicle 110 5 mm Hg, 20
lU/kg/day 112 4mm Hg), serum creatinine (0.31 0.06 vs. 0.32
0.06 mgldl) or serum phosphate (2.41 0.15 vs. 2.46 0.12
mmol/liter). Serum concentration of rhGH (by human GH RIA) 12
hours after the last injection of 5 IU rhGH/kg (which had been
administered every 12 hr) was 13.9 5.2 ng/ml. (The assay
measured < 0.17 ng/ml in rats without rhGH injection). Concom-
itant measurements of rat GH showed that endogenous produc-
tion of GH was suppressed (by specific rat assay 0.9 0.6 ng/ml
vs. 10.2 7.3 ng/ml without rhGH treatment). There was some
increase of IGF-l serum concentration measured with RIA
adapted for rats [181: 479 64 ng/ml without versus 654 87
ng/ml with 10 IU rhGHlkg/day. Kidney dry weight increased with
increasing doses of rhGH, but the kidney/body weight ratio was
not significantly changed by rhGH.
Time course of the effect of rhGH on growth in SD rats
Ten international units of rhGH/kg/day by twice daily s.c.
injections caused a progressive increment of cumulative weight
gain and length gain above the vehicle treated controls (Table 2).
As in experiment 1, there was a consistent increase in the food
conversion ratio, but no significant increase of the kidney dry
weight or heart dry weight/body weight ratio despite treatment for
up to 60 days. The organ weight/body weight ratios changed with
time both in the experimental and in the control groups. Renal
histology did not demonstrate the development of glomeruloscle-
rosis or tubulointerstitial lesions, even after 60 days.
Dose- and time-dependent effect of rhIGF-1 on growth in
SD rats
rhIGF-1 had similar actions on weight gain, length gain, and
food conversion ratio as rhGH (Table 3). There were no effects
on systolic blood pressure, serum creatinine and serum phos-
phate (data not given). Serum concentration of (exogenous)
rhIGF-1 measured with human RIA [10] 12 hours after the last
injection of 4 mg rhIGF-1/kg (given every 12 hours) was 932
102 ng/ml versus 208 29 ng/ml in vehicle injected animals.
rhIGF-1 not only caused a significant increase of kidney dry
weight, but, in contrast to rhGH, also caused a dose dependent
increase of the kidney dry weight/body weight ratio.
After 60 days of treatment with rhIGF-1, kidney weight/body
weight ratio was 0.91 0.05 in rhIGF-1 treated rats and 0.88
0.05 in controls (N = 5 per group). Renal histology did not
demonstrate the development of glomerulosclerosis or tubu-
lointerstitial lesions, even after 60 days of rhIGF-l treatment.
Effect of concomitant treatment with rhGH and rhIGF-1 for
14 days on growth in SD rats
To test whether rhGH and rhIGF-l have additive effects, we
used the doses of rhGH (20 lU/kg/day) and of rhIGF-l (8
mg/kg/day) which had caused maximal effects on weight gain in
the previous experiments 1 and 2 (Table 4). In comparison to
treatment with rhGH, the combined administration of the two
peptides caused a significantly greater weight gain and also a
small but significant (P < 0.05) further increase in length gain.
The combined administration caused a further significant rise of
liver, spleen and of kidney dry weight, but no further increment
of heart and muscle dry weight. While the dry weight/body
weight ratio was not further increased for heart and muscle,
spleen dry weight/body weight ratio (x 10—s) tended to increase
with rhGH + rhIGF-1 (0.69 0.06) versus rhGH alone (0.64
0.05). The same was noted for liver dry weight/body weight
ratio (x l0—) (15.6 0.82 vs. 14.6 0.9).
Consistent with the observations in Tables 1 and 3, rhIGF-1,
but not rhGH, caused a significant increase in kidney dry
weight/body weight ratio. Administration of rhGH together
with IGF-1 caused no further increase.
Development of glomerulosclerosis again was not seen in any
of the treatment groups.
Effects of rhGH and rhIGF-1 on GHR mRNA and IGF-1
mRNA in kidney and liver tissue
Treatment with 10 IU rhGH/kg/day significantly increased
the GHR mRNA in the kidney, but not in the liver (Table 5). At
the same time, an increase of IGF- 1 mRNA was noted which
again was only significant within the kidney. Treatment with 3
g rhIGF-l/kg/day did not cause a significant increase of GHR
mRNA or IGF-l mRNA in kidney and liver.
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Effects of rhGH on renal morphology
Mter treatment of female SD rats with 10 IU rhGH/kg/day by
twice daily s.c. injections for 14 days, kidney volume by
Archimedian principle was significantly greater in rhGH-treated
animals (Table 6). In contrast, the kidney volume/body weight
ratio was not significantly different (vehicle 0.99 0.06 cm3/g;
rhGH 0.97 0.07 cm3/g), but the ratio is based on perfusion
fixed renal tissue. The proportion of kidney volume comprised
of cortex was unchanged. An increase of zonal width and of
glomerular area was noted in rhGH-treated animals. The per-
cent increase of the respective mean values was comparable to
the mean percent increase of kidney volume (+ 10%) and of
body weight (+ 12%).
Effect of treatment with rhGH or rhIGF-1 for five days on
renal DNA/protein ratio in SD rats
Treatment of female SD rats with submaximal doses of rhGH
or rhIGF-1 respectively for five days caused an (insignificant)
increase of kidney dry weight, while protein content increased
significantly (but marginally) together with a striking increase in
DNA content (Table 7). In parallel, an increase of DNA/protein
ratio was noted for rhGH as well as for rhIGF-1 treated animals.
The results suggest that renal growth was accounted for more
by hyperplasia than by hypertrophy.
Effect of treatment with rhGH or rhIGF-1 for five days on
mitosis and PCNA expression of tubular and glomerular cells
in SD rats
In renal intact animals, 10 IU rhGH/kg for four days caused
a significant increase in the number of mitoses demonstrable in
SD rats treated with colchicine for three hours prior to the end
of the experiment (Table 8). A significant increase was seen
both in distal and proximal tubular epithelial cells.
When the baseline number of mitoses was raised by prior
subtotal nephrectomy before administration of rhGH, a further
increment of mitoses was still noted after rhGH. The results
observed with 4 mg rhIGF-1/kg/day were comparable.
To validate the colchicine method with an independent
approach, in a second set of animals the expression of prolifer-
ating nuclear antigen (PCNA) was determined using a murine
1gM monoclonal antibody against human PCNA. The number
of PCNA positive nuclei per glomerular cross section was
significantly increased (P = 0.008; ANOVA) both after rhGH
(3.08 0.53) and rhIGF-1 (2.95 0.41) compared to vehicle
controls (2.2 0.55).
Discussion
The salient features of the present study are the observation
that both rhGH and rhIGF- 1 increase renal weight. The in-
crease of renal weight following administration of rhGH was in
proportion to the increase in body weight. In contrast, admin-
istration of rhIGF-l either alone or in combination with rhGH
increased the renal weight/body weight ratio, suggesting some
selective stimulation of renal growth. After administration of
rhGH, the glomerular volume increased in proportion to the
increase in body weight. Administration of rhGH and of
rhIGF-1 up to 60 days did not cause glomerulosclerosis or
tubulointerstitial changes in female animals.
This systematic analysis extends previous observations of
Guler et al in hypophysectomized rats, which documented that
rhGH increased renal weight in proportion to body weight [34].
Our study shows that rhGH, in doses which are close to those
maximally stimulating body growth, does not significantly affect
the renal and other organ weight/body weight ratio in hypoph-
ysis intact young female SD rats on ad libitum intake of food.
Protein intake has a known stimulatory effect on renal growth
and GFR [12]. The possibility that the effect of rhGH was
mediated by changes in protein intake was not formally ex-
cluded by a pair feeding experiment, but we found no significant
increase of food intake. This is in agreement with previous data
of other [20] and our own groups [8, 18]. In contrast to previous
studies [35], the mortality in our animals was zero. Most of our
experiments lasted for one to two weeks. For longer experi-
ments, one important potential limitation of the efficacy of
(foreign) rhGH or rhIGF-l to rats is antibody production. For
rhGH this is known to occur in female SD rats (A. Skottner-
Lundin, Kabi Pharmacia, Peptide Hormones, Stockholm, per-
sonal communication) after two to three weeks of administra-
tion. In accordance with this, after three weeks the body weight
increment in human peptide hormone treated animals became
identical with that in solvent treated animals (experiments 2 and
3) and growth curves ran parallel, but the initial growth advan-
tage was preserved throughout the experiment.
It is not excluded that more prolonged effective treatment
with rhGH would progressively increase the kidney weightl
body weight ratio in parallel to what has been reported for
transgenic mice expressing GH [15, 36, 37]. But even in
transgenic mice expressing GH this finding has not been re-
ported uniformly [16, 38]. One difficulty of measuring the
kidney weight/body weight ratio in transgenic mice is the fact
that body weight increases rapidly during the first weeks of life,
but decreases continuously during the last weeks before death.
Therefore, different results will be obtained at different stages
of the experiment. This has not been worked out systemati-
cally. It can also not be excluded that a vastly greater amount of
GH produced by the transgenic animals accounts for the
different results. In transgenic mice expressing human GH,
serum hGH levels up to 900,000 ng/ml have been reported [15].
In this respect, it is interesting that the serum concentration of
rhGH in SD rats treated with 10 IU rhGH/kg/day ranged
between 3.3 and 20 ng/m1 12 hours after the last injection. This
is comparable to the serum concentrations in rhGH treated
children with chronic renal failure (mean 20 3.4 ng/ml 12 hr
after injection of 4 IU rhGH/m2; [13]).
In striking contrast to rhGH, rhIGF- 1 dose-dependently
increased the renal weight/body weight ratio above the ratio in
vehicle controls. This result extends the previous findings of
Guler et al [34] in hypophysectomized rats and demonstrates
greater proportional stimulation of renal growth even in hy-
pophysis-intact rats. This result is remarkable since rhIGF-l
increased heart and muscle weight without increasing heart and
muscle weight/body weight ratio. In contrast, spleen and liver
weight/body weight ratios were slightly increased, illustrating
considerable target organ selectivity.
The present finding of a selective renotrophic effect of IGF-1
is in agreement with previous observations in nitrogen re-
stricted rats [39] and in subtotally nephrectomized rats [40]. We
did not specifically address the issue concerning the effects of
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rhIGF-l on renal growth after subtotal nephrectomy. In pilot
experiments it had proven extremely difficult to ablate a stan-
dardized amount of renal tissue. Our results show, however,
that the effect of IGF-1 on renal growth does not require
prestimulation of renal growth by ablation.
The kidney is a known target organ for both GH and IGF- 1.
GH receptors [41] and IGF-1 receptors [20, 42—44] have been
demonstrated and IGF-1 is locally produced in the kidney,
particularly when renal growth is stimulated, such as after
ablation [43, 45, 46], during diabetes mellitus [43] and in
hypersomatotrophic states [47]. The reasons why rhGH and
rhIGF-1 act differently on renal growth are unknown. It is of
note, however, that addition of rhGH to rhIGF-1 (Table 2)
failed to increase the kidney weight/body weight ratio above
that seen in animals given rhIGF-l alone. A significant further
increment in weight gain was noted, however. Interestingly
enough, rhGH increased the GHR mRNA and IGF-l mRNA in
the kidney. These findings would be compatible with the notion
that the effects of IGF-1 are mediated, at least in part, by
pathways different from those mediating the effects of rhGH.
The finding that rhGH differently stimulated GHR mRNA
and IGF-1 mRNA in the kidney and in the liver points to organ
selectivity, and deserves further investigation. It has been
reported that rhGH stimulates GHR mRNA in the liver of
hypophysectomized rats [48]. However, studies in hypophysis-
intact rats have not been reported to date.
We considered that an unchanged renal weight/body weight
ratio after rhGH does not necessarily exclude potential changes
of renal architecture, such as the redistribution of the relative
width of different zones as seen after glucagon or vasopressin
which causes a disproportional increase of medullary width
[49]. The present study, however, showed no significant change
of the relative widths of the different renal zones in rhGH
treated animals. Glomeruli are enlarged in acromegalic patients
[31 and transgenic mice expressing GH [14], IGF-1- [14, 38] or
GH-releasing factor [14, 50]. Potential effects on glomerular
size are of interest, since an increase in glomerular size may be
permissive for the development of glomerulosclerosis. Indeed,
glomerulosclerosis was seen in transgenic mice expressing GH,
but this was not seen in transgenic mice expressing IGF-1 [14].
In our animals on short-term rhGH treatment, glomerular size
increased, but in proportion to the body weight gain, so that the
ratio glomerular volume/body weight did not change. We em-
phasize that glomerulosclerosis or tubulointerstitial lesions
were not seen in our study in female rats, even after prolonged
(60 days) administration of rhGH or rhIGF-1 in doses per body
weight which were considerably in excess of what is adminis-
tered to uremic children [101. The interpretation of these
findings must be cautious in view of antibody formation against
rhGH and rhIGF-1 as discussed above. On the other hand, the
development of glomeruloscierosis has been reported in male
SD rats treated with rhGH for 28 weeks [35] in similar doses. It
is known that male rats are more prone to the development of
glomerulosclerosis than female rats. Whether this explains the
difference of results requires further studies.
Renal growth after ablation involves mainly hypertrophy [51],
although in younger animals hyperplasia does also contribute [52,
53]. To address the relative contribution of hypertrophy and
hyperplasia to the renal growth response to rhGH and rhIGF- 1,
respectively, we examined the renal DNA/protein ratio and the
proportion of renal cells undergoing proliferation and mitosis.
Both methods suggested a major contribution of renal cell prolif-
eration, indicating that in these young female animals the
increment in renal weight mainly involves hyperplasia at least
within the time frame of the study. The results in the young
animals cannot necessarily be extrapolated to older animals.
With respect to rhGH treatment of children with chronic
renal failure, concern has been raised that such treatment
accelerates progression of renal failure by promoting the gene-
sis of glomerulosclerosis. Although our experiments do not
directly bear on this issue, the results are reassuring in that they
indicate that rhGH (i) fails to stimulate renal growth and
glomerular volume out of proportion to the increase in body
weight, and (ii) does not cause glomerulosclerosis in experi-
ments of two months duration. Different effects on kidney
growth should be expected if one considers the use of rhIGF-1
alone or in combination with rhGH for the treatment of stunting
and GH insensitivity [54] in chronic renal failure.
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